Inactive Instrument

Midatech Pharma PLC Stock Nasdaq

Equities

US59564R1041

Biotechnology & Medical Research

Sales 2024 * 26K 33.64K Sales 2025 * 13K 16.82K Capitalization 8.05M 10.42M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 310 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 620 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0.09%
More Fundamentals * Assessed data
Dynamic Chart
Sector Update: Health Care Stocks Rise Late Afternoon MT
Sector Update: Health Care MT
European Equities Close Higher Thursday; UK GDP Grows More Than Expected MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading MT
Biodexa Says Data Show Longevity of Effect of Potential Precancerous Polyps Treatment -- Shares Soar MT
Biodexa Pharmaceuticals Plc Announces Additional Positive Results of Phase 2 Trial of eRapa in Treatment of Precancerous Polyps in the GI Tract - Now 12-Month Data CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
Biodexa Pharmaceuticals plc Announces Departure of Dmitry Zamoryakhin, Chief Scientific Officer and Chief Medical Officer CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
Biodexa Pharmaceuticals PLC Announces Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 CI
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading MT
Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa? At 12 Months in Familial Adenomatous Polyposis CI
More news
Managers TitleAgeSince
Chief Executive Officer 62 19-09-08
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 44 21-07-10
Members of the board TitleAgeSince
Chairman 65 22-06-19
Director/Board Member 65 14-11-12
Chief Executive Officer 62 19-09-08
More insiders
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
More about the company